| ［1］ |
Petri M, Orbai AM, Alarcón GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus［J］. Arthritis Rheum, 2012, 64（8）: 2677⁃2686. DOI: 10.1002/art. 34473.<br />
|
| ［2］ |
Bortoluzzi A, Furini F, Campanaro F, et al. Application of SLICC classification criteria in undifferentiated connective tissue disease and evolution in systemic lupus erythematosus: analysis of a large monocentric cohort with a long⁃term follow⁃up［J］. Lupus, 2017, 26（6）: 616⁃622. DOI: 10.1177/0961203316671814.<br />
|
| ［3］ |
Fatemi A, Samadi G, Sayedbonakdar Z, et al. Anti⁃C1q antibody in patients with lupus nephritic flare: 18⁃month follow⁃up and a nested case⁃control study［J］. Mod Rheumatol, 2016, 26（2）: 233⁃239. DOI: 10.3109/14397595.2015.1074649.<br />
|
| ［4］ |
Zivkovic V, Stankovic A, Cvetkovic T, et al. Anti⁃dsDNA, anti⁃nucleosome and anti⁃C1q antibodies as disease activity markers in patients with systemic lupus erythematosus［J］. Srp Arh Celok Lek, 2014, 142（7⁃8）: 431⁃436.<br />
|
| ［5］ |
Luijten KM, Tekstra J, Bijlsma JW, et al. The Systemic Lupus Erythematosus Responder Index （SRI）; a new SLE disease activity assessment［J］. Autoimmun Rev, 2012, 11（5）: 326⁃329. DOI: 10.1016/j.autrev.2011.06.011.<br />
|
| ［6］ |
Tsianakas A, Herzog S, Landmann A, et al. Successful treatment of discoid lupus erythematosus with fumaric acid esters［J］. J Am Acad Dermatol, 2014, 71（1）: e15⁃17. DOI: 10.1016/j.jaad.2013. 12.004.<br />
|
| ［7］ |
Hannah J, Casian A, D′Cruz D. Tacrolimus use in lupus nephritis: a systematic review and meta⁃analysis［J］. Autoimmun Rev, 2016,15（1）: 93⁃101. DOI: 10.1016/j.autrev.2015.09.006.<br />
|
| ［8］ |
Deng J, Huo D, Wu Q, et al. A meta⁃analysis of randomized controlled trials comparing tacrolimus with intravenous cyclopho⁃sphamide in the induction treatment for lupus nephritis［J］. Tohoku J Exp Med, 2012, 227（4）: 281⁃288.<br />
|
| ［9］ |
Gordon S, Denunzio T, Uy A. Success using tacrolimus in patients with proliferative and membranous lupus nephritis and refractory proteinuria［J］. Hawaii J Med Public Health, 2013, 72（9 Suppl 4）: 18⁃23.<br />
|
| ［10］ |
Ikeuchi H, Hiromura K, Takahashi S, et al. Efficacy and safety of multi⁃target therapy using a combination of tacrolimus, mycophe⁃nolate mofetil and a steroid in patients with active lupus nephritis［J］. Mod Rheumatol, 2014, 24（4）: 618⁃625. DOI: 10.3109/14397595.2013.844397.<br />
|
| ［11］ |
Gu F, Wang D, Zhang H, et al. Allogeneic mesenchymal stem cell transplantation for lupus nephritis patients refractory to conventional therapy［J］. Clin Rheumatol, 2014, 33（11）: 1611⁃1619. DOI: 10.1007/s10067⁃014⁃2754⁃4.<br />
|
| ［12］ |
He J, Zhang X, Wei Y, et al. Low⁃dose interleukin⁃2 treatment selectively modulates CD4+ T cell subsets in patients with systemic lupus erythematosus［J］. Nat Med, 2016, 22（9）: 991⁃993. DOI: 10.1038/nm.4148.<br />
|
| ［13］ |
Jordan N, Lutalo PM, D′Cruz DP. Progress with the use of monoclonal antibodies for the treatment of systemic lupus erythematosus［J］. Immunotherapy, 2015, 7（3）: 255⁃270. DOI: 10.2217/imt.14.118.<br />
|
| ［14］ |
Tesar V, Hruskova Z. Belimumab in the management of systemic lupus erythematosus ⁃ an update［J］. Expert Opin Biol Ther, 2017, 17（7）: 901⁃908. DOI: 10.1080/14712598.2017.1324846.<br />
|
| ［15］ |
Wang B, Higgs BW, Chang L, et al. Pharmacogenomics and translational simulations to bridge indications for an anti⁃interferon⁃α receptor antibody［J］. Clin Pharmacol Ther, 2013, 93（6）: 483⁃492. DOI: 10.1038/clpt.2013.35.<br />
|
| ［16］ |
Matyskiela ME, Zhang W, Man HW, et al. A cereblon modulator （CC⁃220） with improved degradation of ikaros and aiolos［J］. J Med Chem, 2017. DOI: 10.1021/acs.jmedchem.6b01921.<br />
|
| ［17］ |
Ahmed HH, Taha FM, Hel⁃S D, et al. Association between TNF promoter ⁃308 G > A and LTA 252 A > G polymorphisms and systemic lupus erythematosus［J］. Mol Biol Rep, 2014, 41（4）: 2029⁃2036. DOI: 10.1007/s11033⁃014⁃3051⁃7.<br />
|
| ［18］ |
Piotrowski P, Wudarski M, Sowińska A, et al. TNF⁃308 G/A polymorphism and risk of systemic lupus erythematosus in the Polish population［J］. Mod Rheumatol, 2015, 25（5）: 719⁃723. DOI: 10.3109/14397595.2015.1008778.<br />
|
| ［19］ |
Boonsrirat U, Angsuthum S, Vannaprasaht S, et al. Azathioprine⁃induced fatal myelosuppression in systemic lupus erythematosus patient carrying TPMT*3C polymorphism［J］. Lupus, 2008, 17（2）: 132⁃134. DOI: 10.1177/0961203307085255.<br />
|
| ［20］ |
Nagamine A, Takenaka M, Aomori T, et al. Effect of genetic polymorphisms on effectiveness of low⁃dose azathioprine in Japanese patients with systemic lupus erythematosus［J］. Am J Health Syst Pharm, 2012, 69（23）: 2072⁃2078. DOI: 10.2146/ajhp120179.<br />
|
| ［21］ |
Gong LL, Fang LH, Wang HY, et al. Genetic risk factors for glucocorticoid⁃induced osteonecrosis: a meta⁃analysis［J］. Steroids, 2013, 78（4）: 401⁃408. DOI: 10.1016/j.steroids.2013. 01.004.<br />
|
